Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
About Cernum Biosciences Cernum Biosciences supplies independently tested, research-use-only peptides with batch-level quality documentation
Thymosin beta 4 is unusual in this compound class for having controlled human data, RGN-259 ophthalmic solution has been assessed in randomised, placebo-controlled, double-masked Phase 2 and Phase 3 trials in severe dry eye and neurotrophic keratopathy (Sosne et al., Cornea 2015 and Int J Mol Sci 2023)
Sun, B., Jia, X., Yang, F., Ren, G
Injectable use is often marketed as more direct, but neither route has enough high-quality clinical evidence to support routine use for tendonitis
US$ 27.44
US$ 27.81
US$ 29.11
